A5030485519- Cardiac Imaging and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Acute Myocardial Infarction Research
- Frailty in Older Adults
- Cardiac Valve Diseases and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Coronary Interventions and Diagnostics
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Peripheral Artery Disease Management
- Infective Endocarditis Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Cardiovascular Effects of Exercise
- Nutrition and Health in Aging
- Transplantation: Methods and Outcomes
- Trauma and Emergency Care Studies
- Coronary Artery Anomalies
Jacksonville College
2018-2025
Mayo Clinic in Florida
2014-2025
WinnMed
2015-2025
Mayo Clinic in Arizona
2012-2024
Mayo Clinic
2010-2023
RELX Group (Netherlands)
2023
University of Minnesota Rochester
2018
Mayo Clinic Health System
2013-2017
Wheaton Franciscan Healthcare
2015-2017
University of Wisconsin–Madison
2016
Background: There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection 5 ng/L exclude acute myocardial infarction. Per US Food and Drug Administration, hs-cTnT can only report quantitation 6 ng/L, threshold for which there limited data. Our goal was determine whether is safe strategy identify patients at low risk injury Methods: The efficacy (proportion identified as based on baseline hs-cTnT<6 ng/L) identifying low-risk...
<h3>Background</h3> To understand the influence of age on treatment and outcomes, we analyzed largest group patients 75 years or older with ST-segment elevation myocardial infarction treated primary percutaneous coronary intervention (PPCI) in a clinical trial. <h3>Methods</h3> We data from 5745 Assessment Pexelizumab Acute Myocardial Infarction trial July 13, 2004, through May 11, 2006. Age was continuously according to 3 groups: younger than 65 (n = 3410), 74 old 1358), 977). The main...
Pilots face significant occupational risks affecting cardiometabolic health and are subject to regulatory screenings. Cardiometabolic risk factors, cardiac screening findings outcomes among pilots have not been well reported. This study aimed investigate evaluations of asymptomatic aircraft the association between clinical factors outcomes. Asymptomatic referred for assessment January 1991 May 2023 were studied. Baseline characteristics, test evaluated. Major adverse event (MACE) was defined...